Polysialic Acids: Potential Role in Therapeutic Constructs

Biotechnology and Genetic Engineering Reviews

Volumn 16, Issue 1, 1999, Pages 203-216

  Gregoriadis, Gregory ^a   Fernandes, Ana ^a   McCormack, Brenda ^a   Mital, Malini ^a   Zhang, Xiaoqin ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLYSIALIC ACID;

POLYSIALIC ACID;

DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG THERAPY; MOLECULAR WEIGHT; REVIEW;

EID: 0032764280     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.1999.10647975     Document Type: Article

References (26)

1. Benbough, J. E., Wibun, C. N., Rafter, T. N. -A. and Lee, J. (1979). The effect of chemical modification of L-asparaginase on its persistence in circulating biooci of animals. Biochemical Pharmacology 28, 833.
2. Bocci, V. (1987). Metabolism of protein anticancer agents. Pharmacological Therapeutics 34, 1.
3. Cao, S., Zhao, Q., Ding, Z., Ma, L., Yu, T., Wang, J., Feng, Y., and Cheng, Y. (1990). Chemical modifications of enzyme molecules to improve their characteristics. Annals of the New York Academy of Science 613, 460.
4. Davis, S. S., Illum, L., Me Vie, J. -G., and Tomlinson, E., Eds. (1984). Microspheres and Drug Therapy. Amsterdam: Elsevier.
5. Delgado, C., Francis, G. E. and Fister, D. (1992). The uses and properties of PEG-linked proteins. Critical Reviews of Therapeutic Drug Carrier Systems 9, 249.
6. Domb, Aj., KošT, J. and Wiseman, D. M., Eds. (1997). Handbook of Biodegradable Polymers. Amsterdam: Harwood Academic Publishers.
7. Fernandes, A. and Gregoriadis, G. (1996). Synthesis, characterization and properties of sialylated catalase. Biochimica et Biophysica Acta 1293, 92.
8. Fernandes, A. and Gregoriadis, G. (1997). Polysialylated asparaginase: preparation, activity and pharmacokinetics. Biochimica et Biophysica Acta 1341, 26.
9. Flnne, J. (1982). Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain. Journal of Biological Chemistry 257, 11966.
10. Gotschlich, E. C., Fraser, B. A., Nischimura, O., Robbins, J. B. and Liu, T. -Y. (1981). Lipid on capsular polysaccharides of gram-negative bacteria. Journal of Biological Chemistry 256, 8915.
11. Gregoriadis, G. (1995). Engineering liposomes for drug delivery: progress and problems. Trends in Biotechnology 13, 527.
12. Gregoriadis, G., Mccormack, B., Wang, Z and Lifely, R. (1993). Poiysialic acids: Potential in drug delivery. FEBS Letters 315, 271.
13. Gregoriadis, G., Mccormack, B., and Poste, G., Eds (1994). Liposomes in vivo: Control of behaviour. In Targeting of Drugs: Advances in System Constructs. New York: Plenum Press.
14. Haskell, C. M., Canellos, G. P., Leventhal, B. G., Carbone, P. P. and Black, J. B. (1969). L-asparaginase resistance in human leukemia-asparaginase synthetase. Biochemical Phannacology 18, 2578.
15. Howard, J. B. and Carpenter, F. H, (1972). L-asparaginase from Erwinia carotovora. Journal of Biological Chemistry 247, 1020.
16. Keating, M. J., Holmes, R., Lerner, S. and Ho, D. H. (1993). L-asparaginase and PEG asparaginas - past, present and future. Leukemia Lymphoma 10, 153.
17. Kravtzoff, R., Ropers, C., Laguerre, M., Muh, J. P. and Chassaigne, M. (1990). Erythrocytes as carriers for L-asparaginase. Methodological. Journal of Pharmaceutics and Phannacology 42, 473.
18. Lee, V. H. L., Hashlda, M. and Mlzushina, Y., Eds. (1995). Trends and Future Perspectives in Peptide and Protein Drug Delivery. Amsterdam: Harwood Academic Publishers.
19. Mandrell, R. E. and Zollinger, W. D. (1982). Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding Mid equilibrium binding constants. Journal of Immunology 129, 2172.
20. Moreno, C., Llfely, M. R. and Esdaile, J. (1985). Immunity and protection of mice against Neisseria meningitidis group B by vaccination using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide. Infection and Immunity 47, 527.
21. Neerunjun, D. E. and Gregoriadis, G. (1976). Tumour regression with liposome-entrapped asparaginase. Some immunological advantages. Biochemical Society Transactions 4, 133.
22. Nuca, M. L., Shorr, R. and Abuchqwski, A. (1991). The therapeutic value of poly(ethylene-glycol)-modified proteins. Advanced Drug Delivery Reviews 6, 133.
23. Scott, M. D., Lubin, B. H., Zuo, L. and Kuypers, F. A. (1991). Erythocyte defence against hydrogen peroxide: preeminent importance of catalase. Journal of Laboratory Clinical Medicine 118, 7.
24. Torchilln, V. P., and Papisov, M. I. (1994). Why do polyethylene glycol-coated liposomes circulate so long? Journal of Liposome Research 4, 725.
25. Uren, J. R. and Ragin, R. C. (1979). Improvement in the therapeutic, immunological and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginase by attachment of poly-DL-alanyl peptides. Cancer Research 39, 1927.
26. Yunis, A. A., Arimura, G. K. and Russin, D. J. (1977). Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. International Journal of Cancer 19, 128.